Advertisement

Journal of Genetic Counseling

, Volume 21, Issue 6, pp 770–776 | Cite as

Genetic Counseling, Activism and ‘Genotype-First’ Diagnosis of Developmental Disorders

  • Daniel Navon
Article

Abstract

This paper presents a sociological examination of the role of genetic counselors as advocates, not only for patients and their families, but also for genetic conditions themselves. In becoming activists for new disorders, genetic counselors are helping to create new categories that will shape expectations and treatment regimens for both existing patients and those who are yet to be diagnosed. By virtue of their expertise and their position at the intersection of several key professions and constituencies, genetic counselors are likely to play a central role in the way the genetic testing technologies, and especially ‘genotype-first’ diagnosis, impacts the way we understand and categorize developmental difference. I outline some of the promises and dangers that this kind of activism holds for people with developmental disabilities, and particularly the challenge presented by systemic ascertainment bias in the face of genotype-phenotype uncertainty. I argue that new testing techniques like microarray analysis that do not need to be targeted on the basis of clinical presentation throw these challenges into sharp relief, and that the genetic counseling community should consider how to marry advocacy for new genetic conditions with an emphasis on the indeterminate developmental potential of every child.

Keywords

Genetic counseling Activism Social studies of science and medicine Genotype-first diagnosis Ascertainment bias Advocacy 

Notes

Acknowledgments

I am grateful for invaluable feedback from Peter Bearman, Claire Edington and Gil Eyal and the generous support of the USA-Israel Binational Science Foundation, grant number 2010175.

References

  1. Aronowitz, R. A. (1999). Making sense of illness: Science, society and disease. Cambridge University Press.Google Scholar
  2. Bassett, A. S., McDonald-McGinn, D. M., Devriendt, K., Digilio, M. C., Goldenberg, P., Habel, A., et al. (2011). Practical guidelines for managing patients with 22q11.2 deletion syndrome. The Journal of Pediatrics, 159(2), 332.e1–339.e1.CrossRefGoogle Scholar
  3. Beckwith, J. (1972). Science for the people. Annals of the New York Academy of Sciences, 196(4), 236–240.PubMedCrossRefGoogle Scholar
  4. Bosk, C. L. (1992). All God’s mistakes: Genetic counseling in a pediatric hospital (1st ed.). University Of Chicago Press.Google Scholar
  5. Bretelle, F., Beyer, L., Pellissier, M. C., Missirian, C., Sigaudy, S., Gamerre, M., et al. (2010). Prenatal and postnatal diagnosis of 22q11.2 deletion syndrome. European Journal of Medical Genetics, 53(6), 367–370.PubMedCrossRefGoogle Scholar
  6. Brown, A., Phelan, M. C., Patil, S., Crawford, E., Rogers, R. C., & Schwartz, C. (1996). Two patients with duplication of 17p11.2: The reciprocal of the Smith-Magenis syndrome deletion? American Journal of Medical Genetics, 63(2), 373–377.PubMedCrossRefGoogle Scholar
  7. Costain, G., Chow, E. W. C., Ray, P. N., & Bassett, A. S. (2012). Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome. Journal of Intellectual Disability Research.Google Scholar
  8. Deak, K. L., Horn, S. R., & Rehder, C. W. (2011). The evolving picture of microdeletion/microduplication syndromes in the age of microarray analysis: Variable expressivity and genomic complexity. Clinics in Laboratory Medicine, 31(4), 543–564.PubMedCrossRefGoogle Scholar
  9. Driscoll, D. A., Spinner, N. B., Budarf, M. L., McDonald-McGinn, D. M., Zackai, E. H., Goldberg, R. B., et al. (1992). Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. American Journal of Medical Genetics, 44(2), 261–268.PubMedCrossRefGoogle Scholar
  10. Finucane, B. (2011). 2012 National society of genetic counselors presidential address: Maintaining our professional identity in an ever-expanding genetics universe. Journal of Genetic Counseling, 21(1), 3–6.PubMedCrossRefGoogle Scholar
  11. Finucane, B., Haas-Givler, B., & Simon, E. W. (2003). Genetics, mental retardation, and the forging of new alliances. American Journal of Medical Genetics, 117C(1), 66–72.PubMedCrossRefGoogle Scholar
  12. Greenberg, F., Lewis, R. A., Potocki, L., Glaze, D., Parke, J., Killian, J., et al. (1996). Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). American Journal of Medical Genetics, 62(3), 247–254.PubMedCrossRefGoogle Scholar
  13. Gropman, A. L., Duncan, W. C., & Smith, A. C. M. (2006). Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2). Pediatric Neurology, 34(5), 337–350.PubMedCrossRefGoogle Scholar
  14. Heath, D., Rapp, R., & Taussig, K. (2004). Genetic citizenship. A Companion to the anthropology of politics. Blackwell.Google Scholar
  15. Jacobs, P. A., Brunton, M., Melville, M. M., Brittain, R. P., & Mcclemont, W. F. (1965). Aggressive behaviour, mental sub-normality and the XYY male. Nature, 208(5017), 1351–1352.PubMedCrossRefGoogle Scholar
  16. Larson, R. S., & Butler, M. G. (1995). Use of fluorescence in situ hybridization (FISH) in the diagnosis of DiGeorge sequence and related diseases. Diagnostic Molecular Pathology: The American Journal of Surgical Pathology, Part B, 4(4), 274–278.CrossRefGoogle Scholar
  17. Ledbetter, D. H. (2008). Cytogenetic technology – genotype and phenotype. New England Journal of Medicine, 359(16), 1728–1730.PubMedCrossRefGoogle Scholar
  18. Lippmann, A. (1991). The geneticization of health and illness: Implications for social practice. Endocrinologie, 29(1–2), 85–90.PubMedGoogle Scholar
  19. McDonald-McGinn, D. M., & Zackai, E. H. (2008). Genetic counseling for the 22q11.2 deletion. Development Diabilities Research Reviews, 14(1), 69–74.CrossRefGoogle Scholar
  20. McDonald-McGinn, D. M., Zackai, E. H., & Low, D. (1997). What’s in a name? The 22q11.2 deletion. American Journal of Medical Genetics, 72(2), 247–249.PubMedCrossRefGoogle Scholar
  21. McDonald-McGinn, D. M., Kirschner, R., Goldmuntz, E., Sullivan, K., Eicher, P., Gerdes, M., et al. (1999). The Philadelphia story: The 22q11.2 deletion: report on 250 patients. Genetic Counseling (Geneva, Switzerland), 10(1), 11–24.Google Scholar
  22. McDonald-McGinn, D. M., Tonnesen, M. K., Laufer-Cahana, A., Finucane, B., Driscoll, D. A., Emanuel, B. S., et al. (2001). Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: Cast a wide FISHing net! Genetics in Medicine: Official Journal of the American College of Medical Genetics, 3, 23–29.CrossRefGoogle Scholar
  23. Miller, D. T., Adam, M. P., Aradhya, S., Biesecker, L. G., Brothman, A. R., Carter, N. P., et al. (2010). Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies, 86(5), 749–764.Google Scholar
  24. Navon, D. (2011). Genomic designation: How genetics can delineate new, phenotypically diffuse medical categories. Social Studies of Science, 41(2), 203–226.PubMedCrossRefGoogle Scholar
  25. NSGC.org. (2012a). FAQ’s/Definitions. Retrieved February 13, 2012, from http://www.nsgc.org/About/FAQsDefinitions/tabid/97/Default.aspx
  26. NSGC.org. (2012b). FAQs about Genetic Counselors and the NSGC. Retrieved February 13, 2012, from: http://www.nsgc.org/About/FAQsaboutGeneticCounselorsandtheNSGC/tabid/143/Default.aspx
  27. Phelan, M. C. (2011). Interview, March 4th 2011, New York NY.Google Scholar
  28. Phelan, M. C., Rogers, R. C., & Stevenson, R. E. (1988). A de novo terminal deletion of 22q. American Journal Of Human Genetics, 43, A118.Google Scholar
  29. Phelan, M. C., Rogers, R. C., Saul, R. A., Stapleton, G. A., Sweet, K., McDermid, H., et al. (2001). 22q13 deletion syndrome. American Journal of Medical Genetics, 101(2), 91–99.PubMedCrossRefGoogle Scholar
  30. Potocki, L., Bi, W., Treadwell-Deering, D., Carvalho, C. M. B., Eifert, A., Friedman, E. M., et al. (2007). Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. American Journal of Human Genetics, 80(4), 633–649.PubMedCrossRefGoogle Scholar
  31. Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Estabrooks Hahn, S., Strecker, M. N., et al. (2006). A new definition of genetic counseling: National society of genetic counselors’ task force report. Journal of Genetic Counseling, 15(2), 77–83.PubMedCrossRefGoogle Scholar
  32. Shaffer, L. G., Bejjani, B. A., Torchia, B., Kirkpatrick, S., Coppinger, J., & Ballif, B. C. (2007). The identification of microdeletion syndromes and other chromosome abnormalities: Cytogenetic methods of the past, new technologies for the future. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 145C(4), 335–345.CrossRefGoogle Scholar
  33. Shaffer, L. G., Coppinger, J., Morton, S. A., Alliman, S., Burleson, J., Traylor, R., et al. (2011). The development of a rapid assay for prenatal testing of common aneuploidies and microdeletion syndromes. Prenatal Diagnosis, 31(8), 778–787.PubMedCrossRefGoogle Scholar
  34. Smith, A. C., Dykens, E., & Greenberg, F. (1998). Behavioral phenotype of Smith-Magenis syndrome (del 17p11.2. American Journal of Medical Genetics, 81(2), 179–185.PubMedCrossRefGoogle Scholar
  35. Smith, A. C. M., Gropman, A. L., Bailey-Wilson, J. E., Goker-Alpan, O., Elsea, S. H., Blancato, J., Lupski, J. R., et al. (2002). Hypercholesterolemia in children with Smith-Magenis syndrome: del (17) (p11.2p11.2). Genetics in Medicine: Official Journal of the American College of Medical Genetics, 4(3), 118–125.CrossRefGoogle Scholar
  36. Terry, S. F., Terry, P. F., Rauen, K. A., Uitto, J., & Bercovitch, L. G. (2007). Advocacy groups as research organizations: The PXE International example. Nature Reviews Genetics, 8(2), 157–164.PubMedCrossRefGoogle Scholar
  37. Veltman, J. A., & Brunner, H. G. (2010). Understanding variable expressivity in microdeletion syndromes. Nature Genetics, 42(3), 192–193.PubMedCrossRefGoogle Scholar
  38. Verkerk, A., Pieretti, M., Sutcliffe, J., Fu, Y., Kuhl, D., Pizzuti, A., et al. (1991). Identification of A Gene (Fmr-1) containing A Cgg Repeat coincident with a breakpoint cluster region exhibiting length variation in fragile-X syndrome. Cell, 65(5), 905–914.PubMedCrossRefGoogle Scholar
  39. Whitmarsh, I., Davis, A. M., Skinner, D., & Bailey, D. B. (2007). A place for genetic uncertainty: Parents valuing an unknown in the meaning of disease. Social Science & Medicine, 65(6), 1082–1093.CrossRefGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2012

Authors and Affiliations

  1. 1.Department of SociologyColumbia UniversityNew YorkUSA

Personalised recommendations